Genocea Biosciences, Inc. (NASDAQ:GNCA) is expected to report second quarter earnings results, before market open, on Thursday 23rd July 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.4 per share.
Looking ahead, the full year loss are expected at $ 1.6 per share.
Previous Quarter Performance
Genocea Biosciences, Inc. unfold loss for the first quarter of $ 0.46 per share, from the revenue of . The quarterly earnings gained 20.93 percent while revenues compared with the same quarter last year.
According to street consensus, loss of $ 0.35 was expected per share The bottom line results missed street analysts by $ 0.11 or 31.43 percent, at the same time, top line results analysts by $ 16.30 million or .
Stock Performance
According to the previous trading day, closing price of GNCA was $ 3.14, representing a 185.45 % increase from the 52 week low of $ 1.10 and a 18.65 % decrease over the 52 week high of $ 3.86.
The company has a market capital of $ 86.80 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Genocea Biosciences, Inc. will be hosting a conference call at 8:30 AM eastern time on 23rd July 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.genocea.com
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to recall a patients pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify neoantigens and antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase 1/2a clinical trial, designed to direct a patients immune system to attack tumor.
